IL-1α and TGF-β1 as non-Invasive Liver Fibrosis Markers of Chronic Liver Injury among Chronic Liver Diseases Patients in Sharkia Governorate, Egypt |
Article 10, Volume 10, Issue 2, June 2020, Page 108-113 |
Document Type: Original Article |
DOI: 10.21608/AEJI.2020.23397.1050 |
Authors |
Elsayed Saad Abd Elbaser 1; Abeer Hussein Abdelkader1; Samir Abdel-Azim Afifi 2 |
1Tropical Medicine Department, Faculty of Medicine, Zagazig University,Egypt. |
2Internal Medicine Department, Faculty of Medicine, Zagazig University, Egypt. |
Abstract |
Background and study aim: Proper assessment of liver fibrosis and cirrhosis by non- invasive procedures are needed before appropriate management. This study aimed at detecting the role of IL-1α and TGF-β1as non-invasive liver fibrosis markers in chronic liver diseases. Patients and methods: The subjects included in this study were divided into 4 groups. Group1: 15 chronic HCV patients, group 2: 15 HCC patients, group 3: 15 patients with NAFLD, group 4: 15 healthy control subjects. Serum IL-1α and TGF-β1 measured by ELISA to patients and control groups with calculation of FIB-4 and APRI score. Results: IL-1α and TGF-β1 were significantly high in all hepatic patients compared to control group. The highest level of serum TGF-β1 was in HCC patients. There was a positive correlation between serum IL-1α and ALT, AST, ALP and HCV RNA by PCR. There was a negative correlation between IL-1α and TGF-β1. There was a highly significant positive correlation between TGF-β1 and FIB4, APRI score, ALP and AFP. Conclusion: Chronic liver diseases including HCV, HCC and NAFLD were associated with higher levels of IL-1α and TGF-β1 than healthy subjects. |
Keywords |
Key words: chronic liver disease; IL-1α; TGF-β1 |
Main Subjects |
Hepatology |